Search

Your search keyword '"Perez, P"' showing total 145 results

Search Constraints

Start Over You searched for: Author "Perez, P" Remove constraint Author: "Perez, P" Journal journal of thoracic oncology Remove constraint Journal: journal of thoracic oncology
145 results on '"Perez, P"'

Search Results

3. P3.13C.06 Artificial Intelligence Meets SCLC - Integrating Clinicopathological and Whole-Slide Image Data for Prognostic Prediction in SCLC.

4. Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial

5. OA11.06 Cemiplimab Monotherapy for First Line Advanced NSCLC Patients with PD-L1 Expression ≥50%: 5-y Outcomes of EMPOWER-Lung 1

11. EP1.12-26 Retrospective Study About the Impact of Brain Metastases and Cranial Irradiation in Small Cell Lung Cancer

14. Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1–Positive Advanced NSCLC

20. OA21.04 Amivantamab in Patients with Advanced NSCLC and MET Exon 14 Skipping Mutation: Results from the CHRYSALIS Study

24. Whole-Exome Profiling of NSCLC Among African Americans

25. The Phase 3 KEYLYNK-006 Study of Pembrolizumab plus Olaparib versus Pembrolizumab plus Pemetrexed as Maintenance Therapy for Metastatic Nonsquamous Non–Small-Cell Lung Cancer

26. PD.01.03 Genomic Landscape of Primary-Resistance to Osimertinib among Hispanic Patients With EGFR-Mutant Non-Small-Cell Lung Cancer: Results of an Observational Longitudinal-Cohort Study

27. PP.48 Breakthrough SARS-CoV-2 Infection and COVID-19 Disease Severity in Lung Cancer Patients

28. Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer

33. Radiosensitivity of Lung Metastases by Primary Histology and Implications for Stereotactic Body Radiation Therapy Using the Genomically Adjusted Radiation Dose

36. A Phase 1/2 Trial of Ruxolitinib and Erlotinib in Patients with EGFR-Mutant Lung Adenocarcinomas with Acquired Resistance to Erlotinib

38. 10 Osimertinib versus gefitinib followed by osimertinib in patients with EGFR-mutant non-small cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE trial

43. EP16.03-002 Mechanisms of Resistance to First-line Osimertinib in Hispanic Patients with EGFR mutant Non-Small Cell Lung Cancer (FRESTON-CLICaP∫)

48. OA06.02 High-Grade Patterns Cause the Upstaging of Lung Adenocarcinomas From T1 to T2a: A Multicentric Analysis

Catalog

Books, media, physical & digital resources